BRISTOL-MYERS SQUIBB COMPANY (BMY)
Bristol Myers Squibb was incorporated in Delaware in August 1933 as Bristol-Myers Company, successor to a New York business started in 1887. It operates in a single segment engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products.
| Ticker | BMY |
|---|
| Company | BRISTOL-MYERS SQUIBB COMPANY |
|---|
| Exchange | NYSE |
|---|
| Headquarters | PRINCETON, NJ |
|---|
Income statement — period ending 2026-06-30
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent | $3,396,000,000 |
|---|
| Cost of Goods and Services Sold | $3,726,000,000 |
|---|
| Earnings Per Share, Basic | 2 USD/shares |
|---|
| Earnings Per Share, Diluted | 2 USD/shares |
|---|
| Gross Profit (derived) | $9,247,000,000 |
|---|
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | $4,086,000,000 |
|---|
| Income (Loss) from Equity Method Investments | $60,000,000 |
|---|
| Income Tax Expense (Benefit) | $770,000,000 |
|---|
| InterestExpenseNonoperating | $407,000,000 |
|---|
| Investment Income, Interest | $101,000,000 |
|---|
| Net Income (Loss) Attributable to Parent | $3,317,000,000 |
|---|
| Other Nonoperating Income (Expense) | $61,000,000 |
|---|
| Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | $3,316,000,000 |
|---|
| Research and Development Expense | $2,959,000,000 |
|---|
| Restructuring Charges | $56,000,000 |
|---|
| Revenues | $12,973,000,000 |
|---|
| Selling, General and Administrative Expense | $1,826,000,000 |
|---|
| Share-based Payment Arrangement, Noncash Expense | $281,000,000 |
|---|
| Weighted Average Number of Shares Outstanding, Diluted | 2,048,000,000 shares |
|---|
| Weighted Average Number of Shares Outstanding, Basic | 2,042,000,000 shares |
|---|
Sourced from SEC EDGAR/XBRL filings via StockSpectro.
View full interactive research on StockSpectro